HomeCompareUTRK vs ABBV

UTRK vs ABBV: Dividend Comparison 2026

UTRK yields 1000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 UTRK wins by $4.7683925249533696e+36M in total portfolio value
10 years
UTRK
UTRK
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full UTRK calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — UTRK vs ABBV

📍 UTRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUTRKABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UTRK + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UTRK pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UTRK
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, UTRK beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UTRK + ABBV for your $10,000?

UTRK: 50%ABBV: 50%
100% ABBV50/50100% UTRK
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

UTRK
No analyst data
Altman Z
0.4
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UTRK buys
0
ABBV buys
0
No recent congressional trades found for UTRK or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUTRKABBV
Forward yield1000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.7683925249533696e+36M$102.3K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$4.7683311610149396e+36M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: UTRK vs ABBV ($10,000, DRIP)

YearUTRK PortfolioUTRK Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,550$430.00+$100.00MUTRK
2$934,786,450,701$934,679,439,252.34$13,472$627.96+$934786.44MUTRK
3$8,165,787,108,578,292$8,164,786,887,076,042.00$15,906$926.08+$8165787108.56MUTRK
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$19,071$1,382.55+$66665884190957.63MUTRK
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$23,302$2,095.81+$508662171058048128.00MUTRK
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$29,150$3,237.93+$3.62723524842849e+21MUTRK
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$37,536$5,121.41+$2.417368115915061e+25MUTRK
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$50,079$8,338.38+$1.5056740286145463e+29MUTRK
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$69,753$14,065.80+$8.764771002818475e+32MUTRK
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$4.7683925249533696e+36MUTRK

UTRK vs ABBV: Complete Analysis 2026

UTRKStock

Universal Tracking Solutions, Inc. provides global positioning satellite asset tracking systems to monitor the fleets of motor vehicles primarily in the west and southwest United States. The company's products are used to track the location, speed, and heading of a customer's motor vehicle in real time. It also provides software support tools. The company primarily sells its products to the automotive segment of the GPS market through distributors and internal sales force. Universal Tracking Solutions, Inc. was incorporated in 2006 and is based in Gilbert, Arizona.

Full UTRK Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this UTRK vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UTRK vs SCHDUTRK vs JEPIUTRK vs OUTRK vs KOUTRK vs MAINUTRK vs JNJUTRK vs MRKUTRK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.